Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday. These analysts made changes to their price targets on Biomarin Pharmaceutical following earnings announcement. Considering buying BMRN stock? Here's what analysts think: The company posted quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $776.133 million which missed the analyst consensus estimate ...

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.The company posted quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $776.133 million which missed the analyst consensus estimate of $780.629 million.BioMarin Pharmaceutical lowered its FY2025 adjusted EPS guidance from $4.40-$4.55 to $3.50-$3.60 but raised its sales guidance from $3.125 billion-$3.2 ...

mezzotint / Shutterstock.com Futures: The futures are trading higher on Tuesday after a strong start to the week on Wall Street. Traders were buoyed by positive news on the potential for a trade agreement with China and the potential resolution of the TikTok issue. With Wall Street ready for a deluge of earnings this week, the most important of which come from technology giants in the Magnificent 7, it may remain a task for the momentum-driven rally to keep moving higher. Still, with strong retail particip ...

Core Insights - BioMarin Pharmaceuticals (NASDAQ: BMRN) shares have been underperforming, currently trading at their lowest levels since 2013, indicating significant challenges for the company [1] Group 1 - The company is a large biopharmaceutical entity that does not pay dividends, which exacerbates the negative impact of its stock performance [1] - The investing group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as IPOs, mergers & acquisitions, and earnings reports, providing coverage of 10 significant events monthly [1]

Core Insights - BioMarin Pharmaceutical missed both revenue and earnings estimates in the third quarter, indicating potential challenges in financial performance [1] Financial Performance - The company reported lower than expected revenue and earnings for the third quarter [1] - Despite the earnings miss, shares of BioMarin are up 1% in after-hours trading, suggesting a possible positive market reaction or investor sentiment [1]

BioMarin Pharmaceutical (BMRN) reported $776.13 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 4.1%. EPS of $0.12 for the same period compares to $0.91 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $784.4 million, representing a surprise of -1.05%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.15.While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Core Viewpoint - BioMarin Pharmaceutical plans to divest its gene therapy product, which was once anticipated to be a blockbuster treatment for a rare bleeding disorder [1] Company Summary - The gene therapy in question was previously expected to generate significant revenue as a leading treatment option for a specific rare bleeding disorder [1]

Core Insights - BioMarin Pharmaceutical reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of a loss of $0.15 per share, but down from $0.91 per share a year ago [1] - The earnings surprise was +180.00%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenue for the quarter was $776.13 million, slightly missing the Zacks Consensus Estimate by 1.05%, but up from $745.74 million year-over-year [3] Earnings Performance - The company has consistently exceeded consensus EPS estimates, achieving this in four consecutive quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.97, with expected revenues of $819.69 million, and for the current fiscal year, the EPS estimate is $3.54 on revenues of $3.18 billion [8] Stock Performance and Outlook - BioMarin shares have declined approximately 17.1% year-to-date, contrasting with the S&P 500's gain of 15.5% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Industry Context - The Medical - Biomedical and Genetics industry, to which BioMarin belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The performance of BioMarin's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [6][9]

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q3 2025 Earnings Call October 27, 2025 04:30 PM ET Company ParticipantsZaki Molvi - Senior Associate of Biotechnology Equity ResearchJulian Pino - Senior Associate of Biotechnology Equity ResearchTraci McCarty - Head of Investor RelationsAlexander Hardy - President and CEOCristin Hubbard - Chief Commercial OfficerChris Raymond - Managing DirectorBrian Mueller - CFOGreg Friberg - Chief Research and Development OfficerConference Call ParticipantsSalveen Richter - Biotec ...

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q3 2025 Earnings Call October 27, 2025 04:30 PM ET Company ParticipantsZaki Molvi - Senior Associate of Biotechnology Equity ResearchJulian Pino - Senior Associate of Biotechnology Equity ResearchTraci McCarty - Head of Investor RelationsAlexander Hardy - President and CEOCristin Hubbard - Chief Commercial OfficerChris Raymond - Managing DirectorBrian Mueller - CFOGreg Friberg - Chief Research and Development OfficerConference Call ParticipantsSalveen Richter - Biotec ...